| Filed On | Filing |
|---|---|
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption |
| 07 Oct 2026 |
Form 4: Coward D Scott, Director
Granted 125,000 Stock Options (right to buy) |
| 07 Oct 2026 |
Form 4: Kuznik Paul Brian, Director
Granted 125,000 Stock Options (right to buy) |
| 28 Sep 2026 |
Form 3: Kuznik Paul Brian, Director
Holds 65,719 shares of Common Stock |
| 28 Sep 2026 |
Form 3: Coward D Scott, Director
No securities owned |
| 28 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik |
| 15 Sep 2026 |
Form 4: Jones Keith Anthony, Director
Bought 10,000 shares ($5.62K) |
| 25 Aug 2026 | 25-NSE |
| 21 Aug 2026 |
Form 4: Jones Keith Anthony, Director
Bought 10,000 shares ($6.93K) |
| 19 Aug 2026 |
Form 4: Jones Keith Anthony, Director
Bought 30,000 shares ($17.8K) |
| 18 Aug 2026 | SCHEDULE 13D/A |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA... |
| 31 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On July 31, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended July 30, 2026, the bid pric... |
| 28 Jul 2026 | SCHEDULE 13G/A |
| 13 Jul 2026 | SCHEDULE 13D/A |
| 22 Jun 2026 | SCHEDULE 13G |
| 15 Jun 2026 | SCHEDULE 13D/A |
| 12 Jun 2026 |
Form 4: Wallace Max N., Director
Granted 80,000 Stock Options (right to buy) |
Loading...